Menlo Park, Calif.-based Intersect ENT was dinged after the company lowered its guidance for the year to $106 million to $109 million, down from $111 million to $116 million reported during the first-quarter earnings call. Despite closing down at $26.05 in the wake of the second-quarter review and hitting a low of $25.15 Wednesday, the company (NASDAQ:XENT) stood at $26.88 when the market closed Thursday. Read More
